GH RESEARCH PLC DL-025
GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorde… Read more
GH RESEARCH PLC DL-025 (1KA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, GH RESEARCH PLC DL-025 (1KA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GH RESEARCH PLC DL-025 - Net Assets Trend (None–None)
This chart illustrates how GH RESEARCH PLC DL-025's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GH RESEARCH PLC DL-025 (None–None)
The table below shows the annual net assets of GH RESEARCH PLC DL-025 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to GH RESEARCH PLC DL-025's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
GH RESEARCH PLC DL-025 Competitors by Market Cap
The table below lists competitors of GH RESEARCH PLC DL-025 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Saha Pathana Inter-Holding PCL
BK:SPI
|
$304.37 Million |
|
Jiangsu Favored Nanotechnology Co. Ltd. A
SHG:688371
|
$304.40 Million |
|
Shanghai HIUV New Materials Co Ltd
SHG:688680
|
$304.42 Million |
|
Phuoc Hoa Rubber JSC
VN:PHR
|
$304.51 Million |
|
Yantai Longyuan Power Tech
SHE:300105
|
$304.34 Million |
|
Nippon Sheet Glass Company Limited
PINK:NPSGF
|
$304.08 Million |
|
Wereldhav B-Sicafi
BR:WEHB
|
$304.03 Million |
|
Wuhan Langold Real Estate Co Ltd
SHE:002305
|
$303.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GH RESEARCH PLC DL-025's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares GH RESEARCH PLC DL-025's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently GH RESEARCH PLC DL-025 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares GH RESEARCH PLC DL-025's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $338,657,802
- Average return on equity (ROE) among peers: -66.32%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GH RESEARCH PLC DL-025 (1KA) | €- | N/A | N/A | $304.35 Million |
| 09R (09R) | $-2.13 Million | 0.00% | 0.00x | $10.61 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| Argen-X (1AE) | $4.10 Billion | -7.20% | 0.11x | $38.55 Billion |
| 1S90 (1S90) | $131.51 Million | -49.87% | 1.70x | $52.41 Million |
| Strategic Partners A/S (1TB0) | $19.25 Million | -1.55% | 0.22x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.50 Million |
| Intervacc AB (publ) (2E9) | $162.33 Million | -46.52% | 0.15x | $3.64 Million |
| 2F5 (2F5) | $-1.76 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $8.56 Million |